Elraglusib Induces Cytotoxicity via Direct Microtubule Destabilization Independently of GSK3 Inhibition

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Elraglusib is an investigational drug targeting glycogen synthase kinase 3 (GSK3).
• It is currently undergoing clinical trials for various cancer types.
• Its precise cytotoxic mechanism remains under investigation.

Purpose of the Study:

• To definitively identify the molecular target of elraglusib responsible for its cytotoxic effects.
• To clarify whether elraglusib inhibits GSK3 or another cellular component.
• To assess the implications of the drug's mechanism of action on its clinical applications.

Main Methods:

• Utilized biochemical assays to assess elraglusib's interaction with GSK3.
• Employed cellular imaging techniques to observe elraglusib's effects on microtubules (MTs).
• Conducted cytotoxicity assays in cancer cell lines treated with elraglusib.

Main Results:

• Elraglusib demonstrated direct interaction and disruption of microtubules (MTs).
• No significant inhibition of GSK3 by elraglusib was observed.
• Cytotoxicity was directly correlated with MT disruption, not GSK3 inhibition.

Conclusions:

• Elraglusib's primary cytotoxic target is microtubules (MTs), not GSK3.
• This discovery necessitates a re-evaluation of elraglusib's mechanism of action in ongoing clinical trials.
• Understanding the MT-targeting mechanism will aid in predicting patient response and managing side effects.